Sugi Predict

Sugi Predict / Compounds / SCHEMBL12629192

SCHEMBL12629192

SCHEMBL12629192

O=C(O)CCCCCN1C(=O)C=CC1O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 4/20 0.56
▸ PTGS2 P35354 4/20 0.56
▸ GAA P10253 3/20 0.41
▸ TSHR P16473 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ PMP22 Q01453 1/20 0.39
▸ F13A1 P00488 3/20 0.39
▸ PTGER4 P35408 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PTGER2 P43116 1/20 0.38
▸ TBXAS1 P24557 1/20 0.37
▸ FABP4 P15090 1/20 0.37
▸ FABP5 Q01469 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26312049 1.00 PTGS1 (0.56) PTGS1PTGS2GAATSHRLMNA
SCHEMBL18402748 0.93 PTGS1 (0.46) PTGS1PTGS2GAASMN1; SMN2FABP4
SCHEMBL20197866 0.87 PTGS1 (0.40) PTGS1PTGS2GAALMNASMN1; SMN2
SCHEMBL17325350 0.86 PTGS1 (0.41) PTGS1PTGS2SMN1; SMN2FABP4FABP5
SCHEMBL17953261 0.86 PTGS1 (0.41) PTGS1PTGS2SMN1; SMN2FABP4FABP5
SCHEMBL24864496 0.86 PTGS1 (0.39) PTGS1PTGS2GAATSHRLMNA
SCHEMBL19901620 0.86 PTGS1 (0.39) PTGS1PTGS2GAATSHRLMNA
SCHEMBL21276405 0.83 PTGS1 (0.41) PTGS1PTGS2GAATSHRLMNA
SCHEMBL24369547 0.82 MEN1 (0.39) PTGS1PTGS2GAAPMP22SMN1; SMN2
SCHEMBL23181699 0.82 PTGS1 (0.36) PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023125530-A1 ANTIBODY DRUG CONJUGATES BEIGENE, LTD. (KY) 2023-07-06 — — WO disclosed
EP-4039280-A1 TARGETED PYRROLOBENZODIAZEPINE CONJUGATES Seagen Inc. (US) 2022-08-10 — — EP disclosed
WO-2022026915-A9 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. (US) 2022-04-28 — — WO disclosed
US-20210228728-A1 ANTIBODY-DRUG CONJUGATES AND USES THEREOF MABPLEX INTERNATIONAL, LTD. (CN) 2021-07-29 — — US disclosed
US-20200247842-A1 Immune-stimulating soluble doxorubicin-conjugated complex YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO LTD (CN) 2020-08-06 — — US disclosed
EP-3677589-A1 IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-07-08 — — EP disclosed
US-10632210-B2 Peptidomimetic compounds and antibody-drug conjugates thereof GENENTECH, INC. (US) 2020-04-28 — — US disclosed
US-20200087297-A1 QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH, INC. (US) 2020-03-19 — — US disclosed
WO-2020035027-A1 LINKER, ANTIBODY-DRUG CONJUGATE INCLUDING SAME, AND USE THEREOF 中国人民解放军军事科学院军事医学研究院 2020-02-20 — — WO disclosed
US-20190083643-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH, INC. (US) 2019-03-21 — — US disclosed
US-9999681-B2 Peptidomimetic compounds and antibody-drug conjugates thereof GENENTECH, INC. (US) 2018-06-19 — — US disclosed
US-9988420-B2 Cytotoxic peptides and conjugates thereof NOVARTIS AG (CH) 2018-06-05 — — US disclosed
US-20170298139-A1 COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF OPI VI - IP HOLDCO LLC 2017-10-19 — — US disclosed
EP-3130608-A1 (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE Daiichi Sankyo Co., Ltd. (JP) 2017-02-15 — — EP disclosed
US-7964567-B2 Monomethylvaline compounds capable of conjugation to ligands SEATTLE GENETICS, INC. (US) 2011-06-21 — — US disclosed
US-20080248051-A1 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases SEATTLE GENETICS, INC. (US) 2008-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298139-A1 COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF STING1, CGAS, TLR7 PTGS1 2977/4885PTGS2 3195/4885GAA 1286/4885
US-20200247842-A1 Immune-stimulating soluble doxorubicin-conjugated complex TLR3, CD40, TLR6 PTGS1 3187/4885PTGS2 3822/4885GAA 2049/4885
US-10632210-B2 Peptidomimetic compounds and antibody-drug conjugates thereof DNPEP, LNPEP, BCR PTGS1 4377/4885PTGS2 4513/4885GAA 731/4885
US-20210228728-A1 ANTIBODY-DRUG CONJUGATES AND USES THEREOF DARS1, CD2, FCGR2A PTGS1 4265/4885PTGS2 4144/4885GAA 1063/4885
US-20190083643-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF DNPEP, LNPEP, BCR PTGS1 4377/4885PTGS2 4513/4885GAA 731/4885
US-20080248051-A1 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases MMAB, CAD, VIM PTGS1 4626/4885PTGS2 4832/4885GAA 3714/4885
US-20200087297-A1 QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF H1-5, H1-4, CD47 PTGS1 4848/4885PTGS2 4864/4885GAA 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.